ALTERITY THERAPEUTICS

4.2299

22-May-25 11:25:42

15 minutes delayed

Stocks

+0.2199

+5.48%

Today's range

4.0200 - 4.2400

ISIN

N/A

Source

NASDAQ

Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

08 Mar 2023 04:25:00 By Nasdaq GlobeNewswire
Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial

16 Feb 2023 13:44:36 By Nasdaq GlobeNewswire
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model

30 Jan 2023 04:25:00 By Nasdaq GlobeNewswire
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy

25 Jan 2023 04:25:00 By Nasdaq GlobeNewswire

<<
<
1
2
3
4
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.